Compare Infosys Limited (INFY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Sana Biotechnology Inc — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Infosys Limited is far larger — about 49.9× Sana Biotechnology Inc's market cap, and Infosys Limited pays a 4.89% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Sana Biotechnology Inc for 23 Days on average.
| INFY | SANA | |
|---|---|---|
Market Cap | $41.74B | $836.71M |
Volume | 31,354,285 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $20.22 | $5.92 |
52-Week Low | $10.49 | $2.68 |
Typical Hold Time | 27 Days | 23 Days |
Enterprise Value | $39.48B | $749.96M |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro. Analyst consensus is a 'Hold' with a $11.48 price target, indicating modest upside potential from current levels.
The outlook is mixed: strong profitability and recent earnings beats support the stock, but a projected negative net cash flow in 2026 and bearish technical indicators pose risks. Investor sentiment is cautious amid weak Western IT spending concerns, though institutional holdings show confidence. Key risks include competitive pressures and macroeconomic headwinds affecting IT services demand.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
